

Table 2 Quality of randomised trials

Study ID (author, year)	Method of allocation concealment	Blinding			Intention-to- treat analysis	Loss to follow up (%)
		(participants)	(investigators)	(outcome assessors)		
Asberg et al 2009	Not specified	No	No	No	Yes	5.8

Table 3 Results for dichotomous outcomes

Study ID (author, year)	Outcomes	Intervention group (no. of patients with events/no. of patients exposed)	Control group (no. of patients with events/no. of patients not exposed)	Relative risk (RR) [95% CI]	Risk difference (RD) [95% CI]
Asberg et al 2009	Death	9/157	11/164	0.85 (0.36, 2.01)	-0.01 (-0.06, 0.04)
Asberg et al 2009	Opportunistic infection	13/157	11/164	1.23 (0.57, 2.67)	0.02 (-0.04, 0.07)
Asberg et al 2009	CMV disease at 12 months (prevalence)	5/110	3/106	1.61 (0.39, 6.55)	-0.01 (-0.05, 0.03)